Ron Renaud

President & Chief Executive Officer and Member of the Board of Directors

Ron Renaud is Cerevel’s President & Chief Executive Officer, and he serves as a member of our board of directors.

Prior to joining Cerevel, Mr. Renaud served as a partner at Bain Capital Life Sciences from September 2022 to June 2023. Previously, he led Translate Bio as chairman and chief executive officer from 2014 until the close of its acquisition by Sanofi in September 2021. During his tenure, he transformed the company from a start-up platform into a leading mRNA company, following the strategic acquisition of mRNA assets from Shire for $110 million in 2016. Building upon that investment, Mr. Renaud developed a strong corporate culture and a robust research and development organization, and ultimately generated significant returns for shareholders when Sanofi acquired the company for $3.2 billion.

Mr. Renaud was at Idenix Pharmaceuticals from 2007 through 2014, where he served as chief financial officer, chief business officer and finally, president and chief executive officer. At the start of his CEO tenure, the market capitalization of Idenix was $300 million, and through streamlining of operations, increasing employee engagement, and more focused research and development supported by significant capital raises, he led the company to an acquisition by Merck at a value of $3.85 billion.

Earlier in Mr. Renaud‘s career, he was a biotechnology equity research analyst at J.P. Morgan, Schwab Soundview and Bear Stearns. Mr. Renaud also spent more than five years at Amgen, where he held positions in clinical research, investor relations and finance.

Mr. Renaud earned his bachelor’s degree from St. Anselm College and an MBA from the Marshall School of Business at the University of Southern California.